DelveInsight has launched a new report on “Graft Versus Host Disease (GvHD) – Market Insights, Epidemiology, and Market Forecast-2032
DelveInsight’s ”Graft Versus Host Disease (GvHD) – Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Graft Versus Host Disease (GvHD), historical and forecasted epidemiology as well as the Graft Versus Host Disease (GvHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Graft Versus Host Disease Market Report:
1. As per a study by Elgaz S. et al., (2019), “aGvHD occurs in 30–50% of recipients and 14% of all patients suffer severe aGvHD grades 3–4. Chronic GvHD affects 30–70% of patients receiving allo-SCT”.
2. As per the study, approximately 50% of patients who have an allogeneic transplant (transplant using donor cells) develop chronic GVHD.
Key benefits of the Graft Versus Host Disease Market report:
1. Graft Versus Host Disease (GvHD) market report covers a descriptive overview and comprehensive insight of the Graft Versus Host Disease (GvHD) epidemiology and Graft Versus Host Disease (GvHD) market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Graft Versus Host Disease (GvHD) market report provides insights on the current and emerging therapies.
3. Graft Versus Host Disease (GvHD) market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Graft Versus Host Disease (GvHD) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Graft Versus Host Disease (GvHD) market.
Request for sample pages: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
Graft Versus Host Disease (GvHD): Overview
Graft versus host disease (GvHD) is a condition that might occur after an allogeneic transplant. In GvHD, the donated bone marrow or peripheral blood stem cells view the recipient’s body as foreign, and the donated cells/bone marrow attack the body.
There are two forms of GvHD:
- Acute graft versus host disease (aGvHD).
- Chronic graft versus host disease (cGvHD).
As an allogeneic transplant recipient, you might experience either form of GvHD, both forms, or neither.
The key players involved in Graft Versus Host Disease (GvHD) market are:
- Incyte Corportaion/Novartis
- Incyte Corporation
- CSL Behring
- methoxsalen
The launch of the emerging therapies is expected to significantly impact the Graft Versus Host Disease (GvHD) treatment scenario in the upcoming years:-
Drugs covered
- Ruxolitinib
- Itacitinib
- CSL964
- Uvadex
Request a free sample report @https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Graft Versus Host Disease (GvHD) Patient Share (%) Overview at a Glance
5. Graft Versus Host Disease (GvHD) Market Overview at a Glance
6. Graft Versus Host Disease (GvHD) Disease Background and Overview
7. Graft Versus Host Disease (GvHD) Epidemiology and Patient Population
8. Country-Specific Patient Population of Graft Versus Host Disease (GvHD)
9. Graft Versus Host Disease (GvHD) Current Treatment and Medical Practices
10. Unmet Needs
11. Graft Versus Host Disease (GvHD) Emerging Therapies
12. Graft Versus Host Disease (GvHD) Market Outlook
13. Country-Wise Graft Versus Host Disease (GvHD) Market Analysis (2019–2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Graft Versus Host Disease (GvHD) Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Graft versus host disease (GVHD) Pipeline Insights, 2023
“Graft Versus Host Disease (GvHD) Pipeline Insight, 2020” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Graft Versus Host Disease (GvHD) market. A detailed picture of the Graft Versus Host Disease (GvHD) pipeline landscape is provided, which includes the disease overview and Graft Versus Host Disease (GvHD) treatment guidelines.
Graft versus host disease (GVHD) – Epidemiology Forecast 2032
DelveInsight’s ‘Graft Versus Host Disease (GvHD) – Epidemiology Forecast to 2032’ report delivers an in-depth understanding of the disease, historical and forecasted Graft Versus Host Disease (GvHD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/